Pieris Pharmaceuticals Inc
PIRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.4B
Close$
Share Statistics
| Market cap | $1.40 Billion |
|---|---|
| Enterprise Value | $1.20 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.71 |
| Beta | 0.66 |
| Outstanding Shares | 13,085,271 |
Return
| Return on Equity | -21.22% |
|---|---|
| Return on Assets | -18.69% |
| Return on Invested Capital | -8.17% |
Valuation & Multiples
| P/E Ratio | -3.61 |
|---|---|
| PEG | -3.9 |
| Price to Sales | - |
| Price to Book Ratio | 0.8 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -57.49 |
| Enterprise Value to Net Income | -25 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 11, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Palvella Therapeutics, Inc.
14 employees
CEO: Mr. Wesley H. Kaupinen Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamy...